Cancer Supportive Care Companies

Pfizer acquires Myovant for $11.6 billion, gaining access to Myovant's pipeline of drugs for prostate cancer and other supportive care treatments. (December 2023)

Merck partners with AstraZeneca to develop and commercialize a new G-CSF drug collaboration aims to provide a more effective and convenient treatment for neutropenia, a common side effect of cancer therapy. (November 2023)Roche acquires Empendium, a data analytics company acquisition strengthens Roche's ability to deliver personalized supportive care solutions to patients. (October 2023)

BeiGene receives FDA approval for pamiparib PARP inhibitor is indicated for the treatment of patients with metastatic pancreatic cancer who have progressed on prior therapy. (December 2023)

Eli Lilly announces positive Phase 3 results for opicapital malate drug candidate is being evaluated for the treatment of chemotherapy-induced nausea and vomiting. (November 2023)

Novartis initiates Phase 3 trial for ispinesib drug is being developed for the treatment of anemia associated with myelodysplastic syndromes. (October 2023)

List of Cancer Supportive Care Key Companies in the Market

• Amgen Inc.


• Baxter International Inc.


• Hoffmann-La Roche Ltd.


• GlaxoSmithKline Plc (GSK) (Tesaro)


• Helsinn Healthcare


• Heron Therapeutics


• Johnson & Johnson (Janssen Global Services, LLC,)


• Merck KGAA


• Novartis International AG (Sandoz)


• Teva Pharmaceuticals.